deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT05778864

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Sponsor: Eli Lilly and Company

Conditions Renal Insufficiency
Interventions LY3473329
Updated 10 times since 2023 Last updated: Oct 25, 2024 Started: Mar 17, 2023 Primary completion: Sep 6, 2024 Completion: Sep 6, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Renal Insufficiency and is currently completed. Eli Lilly and Company leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2023 – ~May 2023 · 30 days · monthly snapshotNot Yet Recruiting~May 2023 – ~Aug 2023 · 3 months · monthly snapshotRecruiting~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshotRecruiting~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshotRecruiting~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotActive Not Recruiting~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshotCompleted~Nov 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE1

  2. Oct 2024 — Nov 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 5 earlier versions

  1. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE1

  2. Sep 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  3. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  4. May 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  5. Apr 2023 — May 2023 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations